Global biopharmaceutical outsourcing services provider, PCI Pharma Services, has acquired California-based Sherpa Clinical Packaging — a provider of clinical trial supply services.
Acquisition
This acquisition further strengthens PCI’s position in outsourced clinical trial support services and expands its operations to the West Coast of the US. Furthermore, the added capabilities will enable PCI to better support customers from early phases of clinical development through to commercial launch.
“Mark and the team at Sherpa have done an excellent job of building a customer-centric organisation with a strong service reputation,” stated Bill Mitchell, executive vice chairman of PCI. “Their dedication parallels our own commitment to provide the industry-leading customer experience, which makes them a natural fit for PCI.”
Salim Haffar, PCI’s newly appointed CEO commented: “I am delighted to join PCI during this period of rapid expansion and strategic investment which will allow PCI to better partner with our biopharma customers. The acquisition of Sherpa is the next logical step in our Clinical Services expansion strategy, further enhancing our development-stage capabilities and geographic presence.”
“Sherpa’s success is due in large part to our commitment to deliver customers the highest levels of service, quality and reliability,” added Mark Paiz, Sherpa’s founder and CEO. “I strongly believe PCI will continue to build on our success as well as enhance Sherpa with its global network and market-leading reputation.”